We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?
Read MoreHide Full Article
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) is set to report third-quarter 2020 results on Nov 6, before market open.
In the last-reported quarter, the company’s earnings of 5 cents beat the Zacks Consensus Estimate by 106.9%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, the average beat being 32.9%.
Let’s take a look at how things have shaped up prior to this announcement.
Factors at Play
Following a dull second quarter where non-elective healthcare procedures were postponed largely to prioritize coronavirus-led damage control, the third-quarter results are expected to reflect a sort of rebound for Zimmer Biomet on gradual reopening of the economy.
The company is optimistic about recovery in procedure volumes in the United States. Per the last update, this trend was prominent in July, even as some of the states with rising COVID numbers like Florida, Texas and Arizona. With the non-COVID-19 healthcare system continuing to get back to pre-pandemic state, this trend is expected to have continued through the rest of the months of the third quarter.
Zimmer Biomet Holdings, Inc. Price and EPS Surprise
The S.E.T. business (comprising Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma), the company’s major focus area, is expected to have put up a sequentially better performance in the third quarter amid the mayhem. These procedures, being less elective by nature, are expected to have been less impacted in the third quarter. However, some adverse business impacts are expected due to widespread adoption of stay-at-home measures, thus leading to comparatively lesser procedures.
Within the Spine & CMF (Craniomaxillofacial) business, even if we don’t consider the COVID-19 impact, Zimmer Biomet has been witnessing growth deceleration in recent quarters, mainly due to unfavorable pricing. This along with the pandemic-led business disruption is likely to have significantly impacted the business.
Dental product volumes too are once again expected to have declined significantly in the third quarter due to the extremely elective nature of the products, which can be deferred longer than other procedures of Zimmer Biomet. This is likely to have affected revenues. Notably, the products have done extremely well over the last few quarters on increased commercial and channel investments. Although, in its last update, the company talked about certain strategic investments within this business, this might not have contributed to the third-quarter performance.
We expect the company to have registered slightly better performances within its Hips and Knees product portfolios in the United States, which is better equipped for pandemic support compared to the non-U.S. markets of Zimmer Biomet.The nature of the business, which is non-elective, might have continued with sequential improvement in elective procedure trends. Despite COVID-19 hurdles, product introductions like Avenir, supply stability and improved commercial execution are expected to have driven the Hip business in the quarter under review. Also, the company earlier expected to see very strong demand for ROSA, even through the pandemic.
Q3 Estimates
The Zacks Consensus Estimate for total revenues of $904.3 million suggests a 54.5% decline from the prior-year quarter’s reported figure. Also, the consensus estimate for earnings per share is pegged at $1.05, indicating a 40.7% decline from the year-ago period.
What Our Quantitative Model Predicts
Our proven model predicts an earnings beat for Zimmer Biomet this time around. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Zimmer Biomet has an Earnings ESP of +4.10%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank:The company currently carries a Zacks Rank #3.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering as these also have the right combination of elements to beat on earnings this reporting cycle.
Zoetis (ZTS - Free Report) has an Earnings ESP of +3.98% and is a Zacks #2 Ranked stock.
SeaSpine Holdings has an Earnings ESP of + 6.67% and it carries a Zacks Rank of 2 at present.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) is set to report third-quarter 2020 results on Nov 6, before market open.
In the last-reported quarter, the company’s earnings of 5 cents beat the Zacks Consensus Estimate by 106.9%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, the average beat being 32.9%.
Let’s take a look at how things have shaped up prior to this announcement.
Factors at Play
Following a dull second quarter where non-elective healthcare procedures were postponed largely to prioritize coronavirus-led damage control, the third-quarter results are expected to reflect a sort of rebound for Zimmer Biomet on gradual reopening of the economy.
The company is optimistic about recovery in procedure volumes in the United States. Per the last update, this trend was prominent in July, even as some of the states with rising COVID numbers like Florida, Texas and Arizona. With the non-COVID-19 healthcare system continuing to get back to pre-pandemic state, this trend is expected to have continued through the rest of the months of the third quarter.
Zimmer Biomet Holdings, Inc. Price and EPS Surprise
Zimmer Biomet Holdings, Inc. price-eps-surprise | Zimmer Biomet Holdings, Inc. Quote
The S.E.T. business (comprising Surgical, Sports Medicine, Foot and Ankle, Extremities and Trauma), the company’s major focus area, is expected to have put up a sequentially better performance in the third quarter amid the mayhem. These procedures, being less elective by nature, are expected to have been less impacted in the third quarter. However, some adverse business impacts are expected due to widespread adoption of stay-at-home measures, thus leading to comparatively lesser procedures.
Within the Spine & CMF (Craniomaxillofacial) business, even if we don’t consider the COVID-19 impact, Zimmer Biomet has been witnessing growth deceleration in recent quarters, mainly due to unfavorable pricing. This along with the pandemic-led business disruption is likely to have significantly impacted the business.
Dental product volumes too are once again expected to have declined significantly in the third quarter due to the extremely elective nature of the products, which can be deferred longer than other procedures of Zimmer Biomet. This is likely to have affected revenues. Notably, the products have done extremely well over the last few quarters on increased commercial and channel investments. Although, in its last update, the company talked about certain strategic investments within this business, this might not have contributed to the third-quarter performance.
We expect the company to have registered slightly better performances within its Hips and Knees product portfolios in the United States, which is better equipped for pandemic support compared to the non-U.S. markets of Zimmer Biomet.The nature of the business, which is non-elective, might have continued with sequential improvement in elective procedure trends. Despite COVID-19 hurdles, product introductions like Avenir, supply stability and improved commercial execution are expected to have driven the Hip business in the quarter under review. Also, the company earlier expected to see very strong demand for ROSA, even through the pandemic.
Q3 Estimates
The Zacks Consensus Estimate for total revenues of $904.3 million suggests a 54.5% decline from the prior-year quarter’s reported figure. Also, the consensus estimate for earnings per share is pegged at $1.05, indicating a 40.7% decline from the year-ago period.
What Our Quantitative Model Predicts
Our proven model predicts an earnings beat for Zimmer Biomet this time around. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Zimmer Biomet has an Earnings ESP of +4.10%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank:The company currently carries a Zacks Rank #3.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering as these also have the right combination of elements to beat on earnings this reporting cycle.
LHC Group has an Earnings ESP of +1.85% and it currently carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Zoetis (ZTS - Free Report) has an Earnings ESP of +3.98% and is a Zacks #2 Ranked stock.
SeaSpine Holdings has an Earnings ESP of + 6.67% and it carries a Zacks Rank of 2 at present.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>